Clinical Pharmacology Perspective on Anti-Amyloid Therapies for Alzheimer’s Disease
Time: 8:30 am
day: Conference Day One
Details:
- Amyloid hypothesis and antibodies against amyloid: mechanism matters
- Amyloid PET is correlated with clinical endpoints
- Amyloid reduction vs change in clinical endpoint CDR-SB in recent studies with anti-amyloid antibodies
- How anti-amyloid therapies are changing disease progression course in Alzheimer's Disease
